CIK 0000818686
- Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 39148213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-17 | Stark David Matthew Exec. VP Chief Legal Officer | Option exercise | +2,359 | 5,333.39 | ||
| 2020-03-17 | Stark David Matthew Exec. VP Chief Legal Officer | Sale | −2,359 | $7.16 | $17K | 2,974.39 |
| 2020-03-17 | Stark David Matthew Exec. VP Chief Legal Officer | Option exercise · Restricted Share Units | −2,359 | 0 | ||
| 2020-03-17 | O'Grady Brendan P. EVP, North America Commercial | Option exercise | +1,179 | 15,338.49 | ||
| 2020-03-17 | O'Grady Brendan P. EVP, North America Commercial | Sale | −470 | $7.16 | $3K | 14,868.49 |
| 2020-03-17 | O'Grady Brendan P. EVP, North America Commercial | Option exercise · Restricted Share Units | −1,179 | 0 | ||
| 2020-03-17 | Nazzi Gianfranco EVP, International Markets | Option exercise | +874 | 20,189.36 | ||
| 2020-03-17 | Nazzi Gianfranco EVP, International Markets | Sale | −345 | $7.17 | $2K | 19,844.36 |
| 2020-03-17 | Nazzi Gianfranco EVP, International Markets | Option exercise · Restricted Share Units | −874 | 0 | ||
| 2020-03-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +748 | 45,808.51 | ||
| 2020-03-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +266 | 46,074.51 | ||
| 2020-03-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −380 | $7.16 | $3K | 45,694.51 |
| 2020-03-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −134 | $7.16 | $960 | 45,560.51 |
| 2020-03-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −748 | 0 | ||
| 2020-03-17 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −266 | 0 | ||
| 2020-03-17 | Dethlefs Sven EVP Global Marketing&Portfolio | Option exercise | +1,179 | 20,638.7 | ||
| 2020-03-17 | Dethlefs Sven EVP Global Marketing&Portfolio | Option exercise · Restricted Share Units | −1,179 | 0 | ||
| 2020-03-17 | Daniell Richard Exec. VP, European Commercial | Option exercise | +1,297 | 11,016 | ||
| 2020-03-17 | Daniell Richard Exec. VP, European Commercial | Sale | −616 | $7.17 | $4K | 10,400 |
| 2020-03-17 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units | −1,297 | 0 |
Page 56 of 76 · 1,517 trades